Mercado farmacéutico europeo crecerá un 21% hasta 2022...

The advent of new potential blockbusters in Europe is anticipated to position the pharmaceutical industry on a sustained growth pattern through 2022 (2015-2022 CAGR at 3.2%). While oncology* is set to take the lion’s share in terms of growth, innovations have been emerging across several therapy areas. 
As the pharmaceutical pipeline continues to meet the demand for improved outcomes, question marks on the sustainability of the system as we know it continue to rise.

...the number of approvals of top 200 products in Europe (based on 2022 European forecasts) and the average value of the approvals (based on projected/actual sales after 7 years post launch). 
It is quite apparent that the combination of improved clinical design coupled with medical innovation has led to an increase in the numbers of high value products launched by pharmaceutical companies (which in the context of the European market can be considered as a reasonable proxy to measure payers’ willingness to pay for incremental benefits over the standard of care)

  
Among the top 10 bestselling products in 2022 the crown is expected to move from Humira to Xarelto while five therapies will be addressing unmet needs in cancer. 

Click sobre imagen para ampliar

(*) Oncology Market 

Oncology 

The rise of potential breakthrough medications in oncology have accelerated significantly over the past three years with the launch of the first immuno-oncology treatments Opdivo and Keytruda with new promising assets slowly emerging on the horizon such as Roche’s Tecentriq. In the hematology arena, Revlimid and Imbruvica are set to lead the game, despite the latter having a recent set back with UK’s NICE for approval in chronic lymphocytic leukaemia (yet, the drug is still accessible via England’s Cancer Drug Fund). Overall the market is expected to grow at an average annual rate of 8%. 

The funding of these new therapies will remain one of the most pressing challenges facing payers given their use in combination with existing therapies hence doubling – and in some cases tripling – the total cost of therapy. A potential help for payers may come from the expected introduction of biosimilars (Herceptin, Rituxan and Avastin) and generics (Gleevec). However this is likely to prove a challenging battleground for biosimilar players, in particular against Herceptin (trastuzumab) where Roche has deployed a robust lifecycle management strategy with the launch of Perjeta, Kadcyla and the subcutaneous version of Herceptin.(Más)